Why Moderna Stock Was Down 31.8% in Q1 as the S&P 500 Had Its Worst Quarter Since 2022

The first quarter of 2025 was challenging for Moderna, with shares sliding 31.8% as the S&P 500 and Nasdaq Composite also saw losses. The company’s revenues plummeted, leading to a significant decline in sales and lowered guidance for 2025. The resignation of FDA official Peter Marks added to investor concerns, with analysts warning of potential delays in Moderna’s vaccine development programs.

Full Article